Population Pharmacokinetic Model‐Based Dose Selection of Extended‐Release Injectable Olanzapine (TV‐44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia

Documenti analoghi

• Deep‐Learning‐ versus Hypothesis‐Driven Modeling in Model‐Informed Drug Development: A PK/PD Case Study
  di: Roberto Gomeni, et al.
  Pubblicazione: (2026)
• Pharmacokinetics of a Single Subcutaneous Extended‐Release Buprenorphine (Ethiqa XR ) in Healthy Beagles
  di: Kornelia Tiffinger, et al.
  Pubblicazione: (2026)
• Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder
  di: David P. Walling, et al.
  Pubblicazione: (2024)
• Pharmacokinetics‐Based Design of Subcutaneous Controlled Release Systems for Biologics
  di: Abigail K. Grosskopf, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Safety of a Single Subcutaneous or Intramuscular Dose of Ketamine in Healthy Horses
  di: Ana Rangel, et al.
  Pubblicazione: (2025)